HUMA
Humacyte's Second Quarter 2026 Earnings Call Highlights Breakthrough Results in Vascular Injury Indication
Humacyte, a leading developer of bioengineered blood vessels and other medical products, recently announced breakthrough results from its second quarter 2026 earnings call. The company reported exceptional progress across all fronts, including the advancement of the U.S. and global commercial launch of SYMVESS in the vascular injury indication. In